X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Clinical Trials News - 17/Jun 22:06

Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Trial of MTX-101, in Development for Treatment of Autoimmune Diseases

SEATTLE, June 17, 2024. Mozart Therapeutics, a clinical stage biopharmaceutical company focused on the development of CD8 Treg modulators in autoimmune diseases, today announce the dosing of the first cohort of participants in the Company's initial...

Articles similaires

Sorry! Image not available at this time

Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus

pharmabiz.com - 00:00

Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...

Sorry! Image not available at this time

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

drugs.com - 26/Jun 19:06

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

Sorry! Image not available at this time

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

drugs.com - 03/Jul 04:07

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell...

Sorry! Image not available at this time

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

drugs.com - 01/Jul 06:07

STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused...

Sorry! Image not available at this time

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

zacks.com - 27/Jun 14:26

Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin...

Sorry! Image not available at this time

PTC Therapeutics announces interim results from phase 2 PIVOT─HD study of PTC518 in Huntington's disease patients

pharmabiz.com - 22/Jun 00:00

PTC Therapeutics, Inc, a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated...

Sorry! Image not available at this time

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

drugs.com - 24/Jun 23:06

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...

Sorry! Image not available at this time

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

mangaloremirror.com - 02/Jul 12:51

MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...

Sorry! Image not available at this time

Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

drugs.com - 29/Jun 22:06

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or...

Sorry! Image not available at this time

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction

drugs.com - 21/Jun 03:06

CRANBURY, N.J., June 20, 2024. Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that...

Les derniers communiqués